Skip to content

A prospective, single arm clinical study on the efficacy and safety of Kou-Yan-Ning for external use in the treatment of grade III oral mucositis caused by precision antitumor drugs

A prospective, single arm clinical study on the efficacy and safety of Kou-Yan-Ning for external use in the treatment of grade III oral mucositis caused by precision antitumor drugs

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075236
Enrollment
Unknown
Registered
2023-08-30
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug induced oral lesions

Interventions

Traditional Chinese Medicine Group:Kou-Yan-Ning for external use

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. older than 18 years old, regardless of gender; 2. patients who are receiving precision antitumor drugs (including epidermal growth factor receptor antagonists, vascular endothelial growth factor receptor tyrosine kinase inhibitors, immune checkpoint inhibitors, etc.); 3. meet the diagnostic criteria for oral mucositis of who oral toxicity scale grade III; 4. the general condition is good, KPS > 60 points, and the estimated survival time is > 3 months; 5. the functional level of major organs should meet the following criteria: 1) blood routine examination criteria should meet: ANC = 1.5 × 109/l, PLT = 80 × 109/l, Hb = 90g/l 2) biochemical examination should meet the following criteria: TBIL < 1.5 × ULN, alt, AST < 2.5 × ULN subjects with liver metastasis can be < 5 × ULN, bun and Cr = 1 × ULN or endogenous creatinine clearance = 50ml/min (Cockcroft Gault formula); 6. the subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up.

Exclusion criteria

Exclusion criteria: 1. there are other lesions in the mouth and esophagus or a history of drug contact allergy; 2. have received radiotherapy, chemotherapy or any other drugs that may cause oral mucositis within 4 weeks before the start of study treatment; 3. uncontrolled infection and / or metabolic disease; 4. abnormal coagulation function, or known hereditary or acquired bleeding tendency and thrombophilia; 5. the investigator judges other situations that may affect the conduct of clinical research and the judgment of research results. 6. those who have serious oral ulcer, oral infection, oral lichen planus and oral mucosa leukoplakia before the application of precision antitumor drugs.

Design outcomes

Primary

MeasureTime frame
classification of oral mucositis;Changes of NRS at rest and during diet;Effective time;Total effective rate;

Countries

China

Contacts

Public ContactShu Qijin

The First Affiliated Hospital of Zhejiang Chinese Medical University

shuqjhz@163.com+86 136 0570 6566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026